BioNTech SE (NASDAQ: BNTX) reported Q1 EPS of (EUR0.79), EUR0.04 better than the analyst estimate of (EUR0.83). Revenue for the quarter came in at EUR167.7 million versus the consensus estimate of EUR607.8 million.

Still sees Covid-19 vaccine revenue about EUR5 billion, estimate EUR5.05 billion

For earnings history and earnings-related data on BioNTech SE (BNTX) click here.